US8112922005 - Common Stock
SCYNEXIS INC
NASDAQ:SCYX (5/17/2024, 7:25:33 PM)
After market: 2.6559 -0.11 (-4.12%)2.77
+0.36 (+14.94%)
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company is headquartered in Jersey City, New Jersey and currently employs 36 full-time employees. The company went IPO on 2014-05-02. The firm is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. Its Ibrexafungerp has demonstrated activity against a large collection of medically relevant strains of Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera. The firm has received approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection), and for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), respectively.
SCYNEXIS INC
1 Evertrust Plaza, 13th Floor
Jersey City NEW JERSEY 07302
P: 12018845485
CEO: Marco Taglietti
Employees: 36
Website: https://www.scynexis.com/
SCYX stock results show that SCYNEXIS beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips SCYNEXIS (NASDAQ:SCYX) just reported results for the first quarter of 2024.SCYN...
SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the...
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a...
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome...
SCYX stock results show that SCYNEXIS missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Here you can normally see the latest stock twits on SCYX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: